Journal Article

Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities

Ruud P. M. Dings, Xuemei Chen, Debby M. E. I. Hellebrekers, Loes I. van Eijk, Ying Zhang, Thomas R. Hoye, Arjan W. Griffioen and Kevin H. Mayo

in JNCI: Journal of the National Cancer Institute

Volume 98, issue 13, pages 932-936
Published in print July 2006 | ISSN: 0027-8874
Published online July 2006 | e-ISSN: 1460-2105 | DOI: http://dx.doi.org/10.1093/jnci/djj247
Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities

Show Summary Details

Preview

The inhibition of angiogenesis is a promising avenue for cancer treatment. Although some angiostatic compounds are in the process of development and testing, these often prove ineffective in vivo or have unwanted side effects. We have designed, synthesized, and evaluated a small library of nonpeptidic, calixarene-based protein surface topomimetics that display chemical substituents to approximate the molecular dimensions and amphipathic features (hydrophobic and positively charged residues) of the antiangiogenic peptide anginex, which, like many antiangiogenic proteins, consists primarily of an antiparallel β-sheet structure as the functional unit. Two of the topomimetics (0118 and 1097) were potent angiogenesis inhibitors in vitro, as determined by endothelial cell proliferation, migration, and chick embryo chorioallantoic membrane assays. Moreover, both compounds were highly effective at inhibiting tumor angiogenesis and growth in two mouse models (MA148 human ovarian carcinoma and B16 murine melanoma). Our results demonstrate the feasibility of designing nonpeptidic protein surface topomimetics as novel pharmaceutical agents for clinical intervention against cancer through angiostatic or other mechanisms.

Journal Article.  3631 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.